Similar to GIP, the stimulatory effects of GLP-1 on insulin expression and secretion were observed in the presence of high (450 mg/dL) but not normal (99 mg/dL) concentrations of glucose in the cultured cells, indicating the glucose-dependent insulinotropic effect of GLP-1 (117)
After consulting with a weight loss physician, I hesitantly started taking a glucagon-like peptide-1 (GLP-1) receptor agonist (Zepbound, in my case) approximately two years ago, and, in short, its been life-changing for me in the best way
The primary advantage of insulin therapy is that it lowers glucose in a dose-dependent manner and thus can address almost any level of blood glucose
That is a large subcutaneous injection
Tirzepatide is a dual agonist, meaning it can bind to either receptor type
Ask the doctor Harvard Health Letter